ABSTRACT
Background Hong Kong experienced four epidemic waves caused by the ancestral strain of SARS-CoV-2 in 2020-2021 and a large Omicron wave in 2022. Few studies have assessed antibacterial drug prescribing for COVID-19 inpatients throughout the pandemic.
Objectives To describe inpatient antibacterial drug prescribing for COVID-19 patients throughout the pandemic and to determine factors associated with their prescription.
Methods This cohort study used electronic health records of COVID-19 cases admitted to public hospitals in Hong Kong from 21 January 2020 to 30 September 2022. We assessed the prevalence and rates of inpatient antibacterial drug use, using days of therapy/1000 patient days (DOT/1000PD), and examined the association of baseline factors and disease severity with receipt of an inpatient antibacterial drug prescription.
Results Among 65,810 inpatients, 54.0% were prescribed antibacterial drugs at a rate of 550.5 DOT/1000PD. Antibacterial use was lowest during wave 4 (28.0%; 246.9 DOT/1000PD), peaked in early wave 5 (64.6%; 661.2 DOT/1000PD), and then modestly declined in late wave 5 (43.2%; 464.1 DOT/1000PD) starting on 23 May 2022.
Older age, increased disease severity, and residing in an elderly care home were strongly associated with increased odds of prescription, while receiving ≥ 2 doses of COVID-19 vaccines and pre-admission use of coronavirus antivirals were associated with lower odds.
Conclusions The rate of inpatient antibacterial prescribing initially declined during the pandemic, but increased during the Omicron wave when hospital capacity was overwhelmed. Despite the availability of COVID-19 vaccines and antiviral drugs, antibacterial drug use among COVID-19 inpatients remained high into late 2022.
HIGHLIGHTS
The prevalence of antibacterial drug use in hospitalized COVID-19 cases in Hong Kong declined gradually during the first four COVID-19 epidemic waves to 28.0%, but increased to 64.6% with the spread of the Omicron variant in early 2022.
The majority of antibacterial drug prescriptions were for Access and Watch drugs, with limited use of combination therapy or macrolides.
Older age and more severe disease were strongly associated with an inpatient antibacterial drug prescription, while vaccination and initiation of COVID-19-specific antivirals reduced the odds of antibacterial prescription.
Despite moderate-to-high levels of vaccine coverage and the availability of antiviral drugs, 43% of COVID-19 inpatients still received antibacterial drugs in late 2022.
Competing Interest Statement
BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen; and personal fees from PrimeVigilance; outside the submitted work. The authors declare no other competing interests.
Funding Statement
This study was supported by the Research Impact Fund (R7033-18) and Collaborative Research Fund (C7123-20GF) from the Research Grants Council of the Government of Hong Kong Special Administrative Region.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review board of The University of Hong Kong/ Hospital Authority Hong Kong West Cluster. Data used for this analysis was part of the public health response to the pandemic, and informed consent was waived from individual patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Patient data used in the analysis were derived from electronic health records managed by the Hospital Authority and other patient information collected by the Centre for Health Protection during case finding and contact tracing. Access to the underlying data used in this study is subject to the approval of the two agencies.
